National Cancer Institute chooses Luna's agent for preclinical characterization

TriMed Staff | | Health Imaging | Practice Management

The National Cancer Institute has selected Luna Innovations’ MRI contrast agent as a candidate for preclinical characterization by the Nanotechnology Characterization Laboratory.

Luna said the contrast agent is a modified fullerene compound with the potential to provide a completely new approach to enhancing contrast during MRI procedures.

The technology may also prevent the toxicity currently associated with gadolinium, an MRI contrast substance which has been associated with health problems, according to the Roanoke, Va.-based company.

Luna Innovations engages in the research, development and commercialization of technologies in the areas of molecular technology solutions and sensing solutions. 

TriMed Staff

Related Content

Warning: Sidelined reactor could trigger medical isotope shortage
Malpractice watchers: Radiologists, imaging societies should bone up on the ‘science of visual perception’
ACR shares guidance for radiology providers facing IV supply shortages after hurricane
Incidental finding characteristics that warrant communication
AI implementation improves when radiology staff concerns are considered
Hospital organization sees impressive returns from POCUS integration

Around the web

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

Cardiovascular Business
FDA clears AI tool that flags signs of heart disease in chest CT scans

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup